In conclusion, targeting MEX3A, either alone or in combination with RIG-I activation, represents a compelling therapeutic strategy that could disrupt GSC-driven resistance, restore anti-tumor immunity, and ultimately shift the treatment paradigm in GB. This evidence concerns the gene MEX3A and neoplasm.